anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To obtain a skin care preparation suitable for producing good stimulation in an esthetic treatment.  <P>SOLUTION: The skin care preparation comprises (1) an N-acylglutamic acid diester and (2) a polyglycerin having a polymerization degree of 2-5. Preferably the skin care preparation comprises further an alkylene oxide methylsiloxane copolymer. Preferably the skin care preparation contains 10-30 mass% of glycerin and is an oil-in-water-in-oil type dosage form. Preferably, the skin care preparation is a skin protection agent before pack treatment in aesthetics.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Participants recently diagnosed with ALS in a neuromuscular clinic, using the ALS functional rating scale (ALSFRS-R). Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.
Despite advance in the prevention and treatment of esophageal variceal bleeding (EVB), it is still a majorcomplication of portal hypertension with the characteristic of a high mortality around 15\~20% after anepisode of hemorrhage. Following development of EV and EVB, ascites and renal dysfunction occurs in a large portion of patients with time. The international consensus suggested use of non-selective beta-blocker(NSBB) to prevent EVB. Long-term use of NSBB was also found to decrease occurrence of encephalopathy and spontaneous bacterial peritonitis (SBP) and extend survival. Until 2010, Dr. Lebrec et al. found use of NSBB might decrease survival in cirrhotic patients with refractory ascites, therefore they suggested discontinued use of NSBB in these patients. The findings lead to a vigorous dispute between hepatologists. In 2011, the reputable team again found use of NSBB might cause post-paracentesis circulatory dysfunction (PPCD) in cirrhotic patients undergoing a large volume paracentesis. Occurrence of PPCD was known to cause acute kidney injury (AKI) and increase mortality. In 2014, Austria investigators found use of NSBB was associated with increased AKI and shortened survival in patients with SBP. Despite the findings of these studies implicated the harmful aspects of NSBB use, a major debate remained because lack of randomized controlled trial some unequal distribution of patients.Taipei Veterans General Hospital is renowned by its high profile research in portal hypertension and its related complications. The current proposal is aimed to clarify the strategy of NSBB use. We will include patients with EV and EVB. They will be randomized to EVL vs. NSBB for primary prevention And EVL+long-term NSBB vs. EVL+short-term NSBB for secondary prevention. 150 patients will be included in a 3-year period. Primary end-points are formation/progression of ascites, acute kidney injury and survival. The other outcomes such as bleeding, rebleeding, infection and other risk factors will be also analyzed.
ABSTRACT OF THE DISCLOSURE           An aerosol antiperspirant composition is provided that is capable of being dispensed from aerosol containers with low mistiness and dustiness.  The composition includes, an antiperspirant salt in an amount within the range from about 3 to about 30% by weight of the composition and a liquid phase comprising a liquefied propellant in an amount within the range from about 15% to about 95% by weight of the composition.  A bulking agent is provided in an amount within the range from about 0.1 to about 5% by weight of the composition.  A synthetic polymer gum having a viscosity within the range from about 500,000 to about 100 million centistokes at 25°C. is provided to increase the viscosity of the liquid phase.  The synthetic polymer gum  is in solution in the liquid phase in an amount within the range from about 0.05 to about 5% by weight of the composition to inhibit mistiness and dustiness.
All sulfonylurea drugs, including GLUCOTROL XL, are capable of producing severe hypoglycemia [see Adverse Reactions (6)]. Concomitant use of GLUCOTROL XL with other anti-diabetic medication can increase the risk of hypoglycemia. A lower dose of GLUCOTROL XL may be required to minimize the risk of hypoglycemia when combining it with other anti-diabetic medications.

Educate patients to recognize and manage hypoglycemia. When initiating and increasing GLUCOTROL XL in patients who may be predisposed to hypoglycemia (e.g., the elderly, patients with renal impairment, patients on other anti-diabetic medications) start at 2.5 mg. Debilitated or malnourished patients, and those with adrenal, pituitary, or hepatic impairment are particularly susceptible to the hypoglycemic action of anti-diabetic medications. Hypoglycemia is also more likely to occur when caloric intake is deficient, after severe or prolonged exercise, or when alcohol is ingested.

The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. Early warning symptoms of hypoglycemia may be different or less pronounced in patients with autonomic neuropathy, the elderly, and in patients who are taking beta-adrenergic blocking medications or other sympatholytic agents. These situations may result in severe hypoglycemia before the patient is aware of the hypoglycemia.

These impairments may present a risk in situations where these abilities are especially important, such as driving or operating other machinery. Severe hypoglycemia can lead to unconsciousness or convulsions and may result in temporary or permanent impairment of brain function or death.
A 10-week randomized, cross-over study will be carried out to assess the efficacy of pea hull fiber. Participants will complete a 2-week baseline period during which appetite, gastrointestinal symptoms, stool frequency, and stool consistency (transit time) will be collected by paper questionnaire, and participants will collect a single stool. Dietary data (24-hour dietary recalls) will be obtained via phone interviews 3 times during the baseline period. On or about day 15, participants will attend a study visit and complete the Simplified Nutritional Appetite Questionnaire (SNAQ) and Gastrointestinal Symptom Response Scale (GSRS). Participants will be randomized on or about day 15 and consume snacks without pea hull fiber for a 2-week control period, and snacks with added pea hull fiber for a 2-week treatment period separated by a 2-week washout period. In both intervention periods, participants will complete daily questionnaires to assess appetite, gastrointestinal symptoms, and stool frequency and consistency (transit time). Furthermore, they will complete SNAQ and GSRS after the end of each intervention period. The 24-hour dietary recalls will also be collected 3 times during each of the intervention periods. Participants will undergo an additional 2-week washout period after the second intervention period. During washout periods, the same data will be collected as was done during the baseline and intervention periods.Participants will be asked to collect one stool during pre-baseline and weeks 4, 6, 8 and 10 for a total of 5 stools. Stool samples will be analyzed for changes in the microbiota.
An injectable preparation comprising an antibody or antibody fragment for use in a method of treating or reducing the risk of atopic dermatitis or asthma in humans is described. The antibody or antibody fragment of the preparation specifically binds to a human IL4Ra protein that comprises a selected mutation from the group consisting of 175V, E400A, C431R, S503P, Q576R and S752A in SEQ ID NO. 67. The antibody or antibody fragment comprises a human gamma-4 heavy chain constant region that comprises an amino acid selected from the group consisting of a Leu at position 189 shown in SEQ ID NO 73 and an Arg at position 289 shown in SEQ ID NO. 73. The human comprises an IGHG4*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-4 heavy chain constant regions comprising said selected amino acid. The human further comprises a nucleotide sequence encoding said IL4Ra protein comprising said selected mutation.
PURPOSE OF REVIEW: The goal of this chapter was to summarize the literature on childhood adversity and obesity, discuss treatment implications with a case example, and provide recommendations for trauma-informed care for clinicians who work with individuals living with obesity.
RECENT FINDINGS: Adversity in childhood is related directly and indirectly to obesity development. Upstream contributors like adverse childhood experiences (ACEs) and other factors can lead to experiences of toxic stress and increased allostatic load, resulting in downstream effects of obesity and other chronic health conditions. A well-established literature has linked ACEs and obesity suggesting complex interactions between genetic, biological, behavioral, mental health, social, and environmental factors and obesity. Trauma-informed care strategies can be used to optimize care for individuals living with obesity. Care pathways should include individual (clinician) and systemic (organizational) evidence-based interventions.
Coronary artery disease (CAD) is an important contributor to the cardiovascular burden in cancer survivors. The development of coronary ischemia events, myocardial infarction, and heart failure has been associated with many conventional chemotherapeutic agents, new targeted therapies, and immunotherapy. The most frequent pathological manifestations of chemotherapy-mediated coronary damage include acute vasospasm, acute thrombosis, accelerated atherosclerosis development, and microvascular dysfunction. Potential screening techniques for CAD patients include baseline risk factor evaluation, polygenic risk factors, and coronary artery calcium scores. Determining the risk requires consideration of both the type of chemotherapy and the type of cancer being treated. Cardiology-oncology guidelines offer some suggestions for the care of coronary artery disease, which might involve medication, lifestyle changes, and coronary revascularization.
FIELD: respiratory diseases. SUBSTANCE: invention relates to treating respiratory diseases by means of air medium containing sodium chloride particles. When treating bronchial asthma with predominant infection-dependent treatment component and chronic obstructive bronchitis, different sodium chloride concentrations are applied depending on forced expiration volume per 1 sec. When this index is below 60%, treatment course comprising 18-21 actions with 1.0-3.0 mg/cu.m sodium chloride concentration is administered, and when above index is higher than 60%, sodium chloride concentrations are 3.0 to 5.0 mg/cu.m with the same number of actions. EFFECT: enhanced treatment efficiency. 2 tbl
An orally administrable programmed release (i.e. release after a predetermined delay) pharmaceutical preparation comprises a core containing the drug. The core is coated with a hydrophobic material (m.p. 50.90 DEG C) and a surfactant (HLB value 10-16). A water-soluble film forming material may also be incorporated into the coating. There may also be an outer coating which may be an enteric coating or a coating of the same or another drug for prompt release.
The invention relates to a cosmetic formulation for the care of the face and body skin in the form of a face cream, massage cream or face and body oil gel. The cream comprises cellular walls and DNA-fragments which attribute an anti-cancer component to its general effect. The gel and the massage cream contain over 10 mln./g live Lactobacillus bulgaricus cells which have higher longevity due to their medium. The Lactobacilli have a strong anti-phlogistic effect on the skin. The amino acids operate as a quick transport carrier of the medicinal herb compositions contained in the cream, assist in their quick penetration and assimilation, multiplying their effect. The formulation has an anti-phlogistic, hydration and softening, tonic effect and smoothens any wrinkles. It also has an antioxidant effect and retards skin ageing, by reducing the quantity of the free radicals and improves its blood supply. It includes from 1 to 12% of probiotic product containing lyophilization mixture comprising, in wt.%, low lactose skimmed cow's milk from 65 to 75, low lactose lactic hydrolysate from 8 to 12, low lactose skimmed cow's milk fermented with selected strains of Lactobacillus bulgaricus to cellular content up to 2.5 mln./g, from 6.8 to 7.8 glucose, fructose from 5 to 9, aspartam around 0.1%, pectine around 1% and dry monoculture Lactobacillus bulgaricus to cellular content of at least 10 mln./g and crystalline fructose from 6 to 10% in comparison with the lactic mixture.
BACKGROUND: The relationship between obesity and type 2 diabetes with bone health has always been a topic of debate. The weight-adjusted waist index has become a commonly used indicator for assessing central obesity, fat, and muscle mass. However, currently there is no research reporting the association between weight-adjusted waist index and risk of osteoporosis in populations of type 2 diabetes. Therefore, this study aims to provide new information on the association between weight-adjusted waist index and risk of osteoporosis in type 2 diabetes.
METHODS: This cross-sectional study involved 963 patients with type 2 diabetes who were admitted to the Department of Endocrinology of Cangzhou Central Hospital. Multivariate logistic regression models were used to assess the association between weight-adjusted waist index and osteoporosis. The potential nonlinear association was evaluated. The effects of interaction between subgroups were assessed using the likelihood ratio test.
RESULTS: Weight-adjusted waist index was positively associated with the risk of osteoporosis, regardless of traditional confounding factors. For each 1 unit increased in weight-adjusted waist index, the risk of osteoporosis increased by 67%. Furthermore, there was a nonlinear relationship between weight-adjusted waist index and osteoporosis. The subgroup analysis did not reveal any significant interactions.
CONCLUSIONS: Our study indicated a positive association between weight-adjusted waist index and the risk of osteoporosis in adult Chinese type 2 diabetes patients, and this relationship was nonlinear.
This is a randomized controlled study. Some parameters were provided by preliminary test, provided theα=0.05,and β=0.20, the sample size can be estimated to be 2000 by the Open Epi Version 2.Patients will be recruited on the basis of predefined criterias. A researcher will take charge of the recruitment. Participants provide written consent and no financial incentives are provided. They are divided into experimental group and control group randomly. We need to collect their basic information including ages, genders, heights, weights, underlying diseases, surgical procedures and levels classified by ASA. Blood pressure, heart rate and other vital signs during the tube drawing process will be recorded. All the contents needed to be recorded had been compiled into a watch list with detailed instructions for filling in. All the personal information and observation records of participants will be kept in secret and only used for research. Developing standard operating procedure and training all the researchers. A third party will assess the accuracy, completeness and representativeness of registry data. Experimental data will be analysed with the help of statisticians.
The puncture of the bone marrow is a routine medical procedure which is often performed in the field of hematology/oncology. When carefully and appropriately performed, the puncture of the bone marrow has a very low rate of complications and is generally safe for the patient. However, it is an invasive and painful procedure associated with anxiety, especially in patients undergoing repeated punctures. Therefore an appropriate preparation of the patient for the puncture is essential in order to minimize the stress experienced during the procedure. In this regard, there are numbers of both pharmacological and non-pharmacological interventions in pedriatric patients aimed at reducing the punction related pain and anxiety in this patients. Nevertheless an evidence based approach for the pretreatment of the patients is yet to be established. The aim of this study is to investigate three different methods for reducing the pain and anxiety associated with the puncture of the bone marrow in adult patients. Two of the of the investigated methods involve pretreatment of the patients with pharmacological agents (sedative drug or analgetic drug), whereas the third method involves cognitive behavioural pretreatment in form of an audio material. The patients in the control group receive placebo injections.
The utility model relates to a tablet, in particular to a tablet easy for dose dividing. The tablet is rectangular. The whole tablet can be divided into eight equal parts by upper surface nicks (2), into six equal parts by lower surface nicks (4), and into five equal parts by side surface nicks (6). The whole tablet can be divided into 1/2, 1/3, 2/3, 1/4, 3/4, 1/5, 2/5, 3/5, 4/5, 1/6, 5/6, 1/8, 3/8, 5/8 and 7/8 parts along the nicks. The tablet can meet different demands of different patients such as clinical children or elderly people on dosage adjustment and has broad application prospect. When the dose needs to be adjusted, the tablet can be directly broken apart along the nicks by hands; compared with the dividing methods by a knife or scissors or through eyeballing, the dose dividing method of the tablet is easier and safer and can realize more accurate dose; therefore, the tablet has good business prospect.
Provided are mechanisms and processes for determining physiological measurements associated with an infant. In one example, a system includes an infant monitoring device and a monitoring hub. An infant monitoring device interface is configured to receive measurement data transmitted wirelessly from multiple sensors associated with an infant monitoring device. The infant monitoring device is configured to be worn by an infant. A camera interface is configured to receive sensor data from a camera. The camera located in proximity to the infant. The sensor data comprises visual data of the infant. A processor is configured a physiological measurement of the infant based on the measurement data received from the infant monitoring device and the visual data received from the camera.
AIMS: Cognitive dysfunction associated with chronic pain may be caused by impaired synaptic plasticity. Considering the impact of silent information regulator 1 (SIRT1) on synaptic plasticity, we explored the exact role of SIRT1 in cognitive impairment caused by chronic pain.
METHODS: We evaluated the memory ability of mice with the fear conditioning test (FCT) after spared nerve injury (SNI) model. Western blotting and immunofluorescence were used to analyze the expression levels of SIRT1. Hippocampal synaptic plasticity was detected with Golgi staining, transmission electron microscopy, and long-term potentiation (LTP). In the intervention study, AAV9-CaMKIIα-Cre-EGFP was injected to SIRT1flox/flox mice to knockdown the expression levels of SIRT1. Besides, SNI mice were injected with AAV2/9-CaMKIIα-SIRT1-3*Flag-GFP or SRT1720 to increase the expression levels or enzymatic activity of SIRT1.
RESULTS: Our current results indicated that cognitive function in SNI mice was impaired, SIRT1 expression in glutaminergic neurons in the hippocampal CA1 area was downregulated, and synaptic plasticity was altered. Selective knockdown of SIRT1 in hippocampus damaged synaptic plasticity and cognitive function of healthy mice. In addition, the impaired synaptic plasticity and cognitive dysfunction of SNI mice could be improved by the upregulation of SIRT1 expression or enzyme activity.
CONCLUSIONS: Reduced SIRT1 expression in hippocampus of SNI mice may induce cognitive impairment associated with chronic pain by mediating the impaired synaptic plasticity.
Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact the safe and effective use of concomitant medications. For example, altered blood glucose control resulting in serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies. Management of hypoglycemia in these cases required either discontinuation or dose modification of concomitant medications used for diabetes treatment.

Frequent monitoring of relevant laboratory parameters (e.g., International Normalized Ratio [INR] in patients taking warfarin, blood glucose levels in diabetic patients) or drug concentrations of concomitant medications such as cytochrome P450 substrates with a narrow therapeutic index (e.g., certain immunosuppressants) is recommended to ensure safe and effective use. Dose adjustments of concomitant medications may be necessary.

Table 4 provides a listing of established or potentially clinically significant drug interactions. The drug interactions described are based on studies conducted with either sofosbuvir and velpatasvir tablets (400 mg/100 mg), or sofosbuvir and velpatasvir as individual agents, or are predicted drug interactions that may occur with sofosbuvir and velpatasvir [see Warnings and Precautions (5.2, 5.3) and Clinical Pharmacology (12.3)].
Liquid coating compositions comprise a water-soluble ethylene oxide polymer of molecular weight greater than 200,000 (which may have a melt viscosity at 150 DEG  C. of 15,000 to 16,000 poises) and a physiologically acceptable water-insoluble film-forming substance, preferably a cellulose acetate phthalate both dissolved in a volatile non-aqueous organic solvent, such as a mixture of acetone and ethyl alcohol.  The molecular weight of the ethylene oxide polymer may be up to about 5 million and it may have a softening point of about 65 DEG  to 70 DEG  C.  The compositions may contain plasticizing agents such as diethyl phthalate, castor oil, corn oil, sesame oil or propylene glycol.  They may also contain non-toxic dyes, lakes or pigments.  The ethylene oxide polymer may be present in the compositions to the extent of 2-3% weight/volume and the cellulose acetate phthalate to the extent of about 5-7% weight/volume in the solvent. The compositions are intended to be used for the coating of pharmaceutical tablets.ALSO:Liquid coating compositions for coating pharmaceutical tablets comprise a water-soluble ethylene oxide polymer of molecular weight greater than about 200,000 (which may have a melt viscosity at 150 DEG C. of 15,000 to 16,000 poises) and a physiologically acceptable water-insoluble film-forming substance, preferably a cellulose acetate phthalate, both dissolved in a volatile non-aqueous organic solvent, such as a mixture of acetone and ethyl alcohol.  The molecular weight of the ethylene oxide polymer may be up to about 5 million and it may have a softening point of about 65 to 70 DEG C.  The compositions may contain plasticizing agents such as diethyl phthalate, castor oil, corn oil, sesame oil or propylene glycol.  They may also contain non-toxic dyes, lakes or pigments.  The ethylene oxide polymer may be present in the compositions to the extent of 2-3% weight/volume and the cellulose acetate phthalate to the extent of about 5-7% weight/volume in the solvent.